Shuttle Pharmaceuticals Holdings Inc

This advisory (non-binding) proposal asks stockholders to approve the Company’s disclosed compensation of its Named Executive Officers (NEOs) as presented in the Executive Compensation section. Management seeks shareholder endorsement to signal support for the structure and levels of pay, including base salaries, bonuses, RSU awards, and other compensation elements disclosed; although non-binding, the Compensation Committee will consider the vote when setting future pay. The Board frames the proposal as consistent with best practices and believes the program aligns executives’ interests with stockholder value through equity-based awards and performance conditions. The primary risk for shareholders is that approval does not legally constrain future compensation decisions, while a negative vote would represent dissatisfaction and could force the Company to materially revisit its pay programs or engage in enhanced shareholder engagement. Company-specific context: the Company has recently undergone management transitions and engaged consulting arrangements for its interim CEO, and pay disclosures include prior grants and settlement terms for departed executives, which may influence shareholder sentiment. The advisory vote provides accountability and a direct mechanism for shareholders to express views on pay philosophy, especially given recent executive changes and the Company’s need to retain and attract talent amid financing and Nasdaq compliance pressures. Management argues that the disclosed arrangements are reasonable given market practice and the Company’s stage; opponents (if any) would likely focus on special awards to departing executives or the scale of equity grants relative to the public float. The Compensation Committee will weigh the outcome when designing future compensation, and a negative result could trigger more substantive changes or outreach. Overall, the proposal is routine for public companies but is an important governance signal for assessing alignment between pay and performance at a company undergoing operational and leadership transitions.

This management proposal requests shareholder authorization to amend the Certificate of Incorporation to permit the Board to effect one or more reverse stock splits of outstanding common stock at any whole-number ratio between 1-for-2 and 1-for-150, exercisable at the Board’s discretion. Management frames the request as a pre-approved, flexible tool to increase the per-share trading price and preserve the Company’s Nasdaq listing in the face of market volatility and historical bid-price compliance issues (the Company previously executed 1-for-8 and 1-for-25 splits). The Board argues that approving a range — rather than a single ratio — preserves optionality to address future market conditions without returning to shareholders each time a split may be prudent. Key governance implications include the relative increase in authorized but unissued shares following a split (which could enable future dilutive issuances without stockholder approval) and potential anti-takeover concerns the Company discloses. The transaction may benefit liquidity and listing status if it produces a durable per-share price increase, but there is no guarantee of sustained price appreciation and some investors view reverse splits negatively; odd-lot holdings and fractional-share cash-outs are practical consequences. The proposal’s success depends on shareholders’ willingness to vest substantial discretion in the Board to act opportunistically; the Board retains the right not to implement the split even if authorized. For vote-sensitive investors, additional mitigation could include limiting the maximum ratio or requiring a two-step approach; however, management asserts flexibility is necessary given uncertain market conditions and potential need for repeated splits. Overall, the proposal is a defensive and operational governance tool intended to preserve listing and capital-market access; its trade-offs are predictable — potential reduction in share count and increased authorized shares versus the uncertain market reception and dilution risk associated with future issuances.

This management proposal asks shareholders to authorize the Board to adjourn the Annual Meeting one or more times to solicit additional proxies if there are insufficient votes to approve one or more proposals. Management argues this authority allows the Company to ensure adequate consideration and voting participation, particularly for non-routine matters that may generate broker non-votes or require targeted outreach. The practical effect is procedural: approval gives the Board flexibility to extend the meeting rather than accepting defeat on contested proposals and can help secure quorum or majority thresholds when needed. From a governance perspective, adjournment authority is common and typically uncontroversial, but opponents might view repeated adjournments as delaying tactics that could entrench management or frustrate timely shareholder decisions. The Company discloses that proxies already submitted may be revoked prior to use, which preserves shareholder agency, but the Board retains sole discretion to determine necessity. The vote standard is a majority of votes present and entitled to be cast; abstentions count as against. For institutional investors, this proposal is routine but should be evaluated in light of the Company’s overall responsiveness to shareholder concerns — frequent use could signal poor engagement or contested governance issues. Overall the proposal is a governance mechanism to facilitate appropriate vote outcomes and further solicitation if required, with limited substantive impact on corporate policy beyond timing and vote-seeking.